Twist Bioscience (TWST) revenue breakdown
By product, NGS tools is the largest at 55% of fiscal 2025 revenue; Antibody discovery grew fastest, 58% a year over 5 years.
By region, Americas is the largest at 60% of fiscal 2025 revenue; APAC grew fastest, 39% a year over 5 years.
Revenue by product
Fiscal years, as Twist Bioscience reports them in its 10-K filings; fiscal 2025 total $377M.
| Products | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| NGS tools | $44M | $73M | $99M | $124M | $169M | $208M | 55% |
| Synthetic genes | $35M | $39M | $62M | $74M | $93M | $114M | 30% |
| Antibody discovery | $2M | $7M | $24M | $23M | $20M | $23M | 6% |
| Oligo pools | $5M | $8M | $12M | $14M | $17M | $20M | 5% |
| DNA libraries | $4M | $6M | $6M | $10M | $14M | $11M | 3% |
Revenue by region
Fiscal years, as Twist Bioscience reports them in its 10-K filings; fiscal 2025 total $377M.
| Regions | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| Americas | $59M | $78M | $122M | $151M | $194M | $226M | 60% |
| EMEA | $26M | $44M | $62M | $71M | $93M | $124M | 33% |
| APAC | $5M | $10M | $19M | $22M | $27M | $27M | 7% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for TWST.
Open TWST in InvestinglyQuestions
Where does Twist Bioscience make its money?
In fiscal 2025, by product: NGS tools $208M, Synthetic genes $114M, Antibody discovery $23M, Oligo pools $20M, DNA libraries $11M.
From Twist Bioscience's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.